trial

Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia

NCTId NCT01396421
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 636 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2014-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
636 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-07
Primary completion
2014-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Investigators

1
Aleksandar Skuban, M.D.Study Director

Sites

0 total

Linked catalysts

1
Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatmen — primary completion2014-01

Facts & assertions

4 sourced
Enrollment
636
Phase
PHASE3
Primary Completion Date
2014-01
Status
COMPLETED
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Acute Schizophrenia
indication
investigator
Aleksandar Skuban, M.D.
person